Home » Stocks » Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc. (DCPH)

Stock Price: $52.33 USD -1.08 (-2.02%)
Updated Jul 16, 2020 1:44 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 2.92B
Revenue (ttm) 25.06M
Net Income (ttm) -217.68M
Shares Out 55.86M
EPS (ttm) -4.66
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 16, 2020
Last Price $52.33
Previous Close $53.41
Change ($) -1.08
Change (%) -2.02%
Day's Open 52.86
Day's Range 51.39 - 53.31
Day's Volume 116,011
52-Week Range 19.88 - 71.11

More Stats

Market Cap 2.92B
Enterprise Value 2.25B
Earnings Date (est) Aug 11, 2020
Ex-Dividend Date n/a
Shares Outstanding 55.86M
Float 33.95M
EPS (basic) -4.56
EPS (diluted) -4.66
FCF / Share -3.78
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 4.40M
Short Ratio 7.27
Short % of Float 11.25%
Beta 2.17
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 116.64
PB Ratio 4.36
Revenue 25.06M
Operating Income -226.96M
Net Income -217.68M
Free Cash Flow -202.22M
Net Cash 674.40M
Net Cash / Share 12.07
Gross Margin 99.75%
Operating Margin -905.61%
Profit Margin -868.60%
FCF Margin -806.89%
ROA -28.00%
ROE -47.72%
ROIC -56.50%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (12)

Buy 10
Overweight 0
Hold 2
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(38.54% upside)
Current: 52.33
Target: 72.50
*Average 12-month price target from 12 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Gross Profit25.00----
Operating Income-201-104-50.94-25.84-17.61
Net Income-192-99.85-50.28-25.94-19.82
Shares Outstanding42.8735.3916.7911.634.25
Earnings Per Share-4.48-2.82-2.99-2.23-4.67
Operating Cash Flow-149-86.78-36.70-23.09-13.27
Capital Expenditures-4.94-1.13-0.41-0.22-0.14
Free Cash Flow-154-87.91-37.11-23.31-13.41
Cash & Equivalents58029419757.4625.78
Total Debt17.6513.181.481.671.87
Net Cash / Debt56228119555.7923.91
Book Value546280184-140-115
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Deciphera Pharmaceuticals, Inc.
Country United States
Employees 255
CEO Steven L. Hoerter

Stock Information

Ticker Symbol DCPH
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: DCPH
IPO Date September 28, 2017


Deciphera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. Its lead drug candidate is ripretinib for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas. The company is also developing immunokinase inhibitors comprising DCC-3014 that is in Phase I trial for the treatment of tenosynovial giant cell tumors; and Rebastinib, which is in Phase Ib/II trial to treat solid tumors, as well as to investigate in combination with chemotherapy for the treatment of multiple solid tumors. In addition, its preclinical stage drug candidate is DCC-3116 for the treatment of RAS mutant cancers. The company was founded in 2003 and is headquartered in Waltham, Massachusetts.